Lipocine (NASDAQ:LPCN) Upgraded to “Sell” at Wall Street Zen

Lipocine (NASDAQ:LPCN) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective (up previously from $7.00) on shares of Lipocine in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Lipocine Price Performance

LPCN stock opened at $8.49 on Friday. Lipocine has a fifty-two week low of $2.52 and a fifty-two week high of $12.37. The stock has a market capitalization of $47.12 million, a price-to-earnings ratio of -8.32 and a beta of 0.99. The business has a fifty day moving average price of $6.88 and a 200 day moving average price of $4.34.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). Lipocine had a negative return on equity of 30.65% and a negative net margin of 126.67%.The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.24 million.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Citadel Advisors LLC bought a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,247 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned 0.26% of Lipocine as of its most recent filing with the Securities and Exchange Commission. 9.11% of the stock is owned by institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.